Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Journal of Visualized Experiments : Jove
|
May 7, 2014
Surface passivation for single-molecule protein studies
Stanley D Chandradoss, Anna C Haagsma, Young Kwang Lee, et al.
The CRISPR Journal
|
August 18, 2021
Cas4-Cas1 Is a Protospacer Adjacent Motif-Processing Factor Mediating Half-Site Spacer Integration During CRISPR Adaptation
Sebastian N Kieper, Cristóbal Almendros, Anna C Haagsma, et al.
Nucleic Acids Research
|
January 24, 2018
Viral suppressors of RNAi employ a rapid screening mode to discriminate viral RNA from cellular small RNA
Mohamed Fareh, Jasper van Lopik, Iason Katechis, et al.
Nucleic Acids Research
|
January 12, 2018
Viral suppressors of RNAi employ a rapid screening mode to discriminate viral RNA from cellular small RNA
Mohamed Fareh, Jasper van Lopik, Iason Katechis, et al.
Antimicrobial Agents and Chemotherapy
|
December 17, 2008
Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue
Anna C Haagsma, Rooda Abdillahi-Ibrahim, Marijke J Wagner, et al.
Science (New York, N.Y.)
|
August 27, 2021
The gRAMP CRISPR-Cas effector is an RNA endonuclease complexed with a caspase-like peptidase
Sam P B van Beljouw, Anna C Haagsma, Alicia Rodríguez-Molina, et al.
Nature
|
September 30, 2021
Mechanism for Cas4-assisted directional spacer acquisition in CRISPR-Cas
Chunyi Hu, Cristóbal Almendros, Ki Hyun Nam, et al.
Cell Reports
|
March 29, 2018
Cas4 Facilitates PAM-Compatible Spacer Selection during CRISPR Adaptation
Sebastian N Kieper, Cristóbal Almendros, Juliane Behler, et al.
The CRISPR Journal
|
July 14, 2022
Adaptation by Type V-A and V-B CRISPR-Cas Systems Demonstrates Conserved Protospacer Selection Mechanisms Between Diverse CRISPR-Cas Types
Wen Y Wu, Simon A Jackson, Cristóbal Almendros, et al.
Annals of the Rheumatic Diseases
|
July 18, 2008
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
M K Reinders, C Haagsma, T L Th A Jansen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Journal of Visualized Experiments : Jove
|
May 7, 2014
Surface passivation for single-molecule protein studies
Stanley D Chandradoss, Anna C Haagsma, Young Kwang Lee, et al.
The CRISPR Journal
|
August 18, 2021
Cas4-Cas1 Is a Protospacer Adjacent Motif-Processing Factor Mediating Half-Site Spacer Integration During CRISPR Adaptation
Sebastian N Kieper, Cristóbal Almendros, Anna C Haagsma, et al.
Nucleic Acids Research
|
January 24, 2018
Viral suppressors of RNAi employ a rapid screening mode to discriminate viral RNA from cellular small RNA
Mohamed Fareh, Jasper van Lopik, Iason Katechis, et al.
Nucleic Acids Research
|
January 12, 2018
Viral suppressors of RNAi employ a rapid screening mode to discriminate viral RNA from cellular small RNA
Mohamed Fareh, Jasper van Lopik, Iason Katechis, et al.
Antimicrobial Agents and Chemotherapy
|
December 17, 2008
Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue
Anna C Haagsma, Rooda Abdillahi-Ibrahim, Marijke J Wagner, et al.
Science (New York, N.Y.)
|
August 27, 2021
The gRAMP CRISPR-Cas effector is an RNA endonuclease complexed with a caspase-like peptidase
Sam P B van Beljouw, Anna C Haagsma, Alicia Rodríguez-Molina, et al.
Nature
|
September 30, 2021
Mechanism for Cas4-assisted directional spacer acquisition in CRISPR-Cas
Chunyi Hu, Cristóbal Almendros, Ki Hyun Nam, et al.
Cell Reports
|
March 29, 2018
Cas4 Facilitates PAM-Compatible Spacer Selection during CRISPR Adaptation
Sebastian N Kieper, Cristóbal Almendros, Juliane Behler, et al.
The CRISPR Journal
|
July 14, 2022
Adaptation by Type V-A and V-B CRISPR-Cas Systems Demonstrates Conserved Protospacer Selection Mechanisms Between Diverse CRISPR-Cas Types
Wen Y Wu, Simon A Jackson, Cristóbal Almendros, et al.
Annals of the Rheumatic Diseases
|
July 18, 2008
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
M K Reinders, C Haagsma, T L Th A Jansen, et al.
Page
of 3